Delving into the Latest Updates on Shanghai Kangdai Biomedical Technology Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Shanghai Kanda Biotechnology Co., Ltd. is a leading company in the field of biotechnology, specializing in research, development, production and sales of high-tech bio-products. With a strong R&D team and advanced production facilities, Kanda Biotechnology has achieved many outstanding achievements in the field of biotechnology and is committed to providing customers with quality products and services.

Tags

Immune System Diseases

Neoplasms

Skin and Musculoskeletal Diseases

Fusion protein

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Fusion protein	1
Biological products	1

Top 5 Target	Count

HER2(Receptor tyrosine-protein kinase erbB-2)	1

This phase 1 study will consist of two parts: Phase 1a is a single-dose study, and will evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary pharmacodynamics (PD) in healthy participants. Phase 1b is a multiple doses study, and will evaluate the safety, tolerability, PK and preliminary PD in participants with rheumatoid arthritis (RA).

Start Date06 Jan 2024

Sponsor / Collaborator

Shanghai Kangdai Biomedical Technology Co., Ltd.

CTR20230746

/ RecruitingPhase 1/2

一项评价 KD6001 注射液联合特瑞普利单抗在晚期黑色素瘤患者中安全性、耐受性、药代动力学和初步疗效的临床研究

[Translation] A clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of KD6001 injection combined with toripalimab in patients with advanced melanoma

评价 KD6001 注射液联合特瑞普利单抗在晚期黑色素瘤患者中安全性、耐受性、药代动力学和初步疗效

[Translation]

To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of KD6001 injection combined with toripalimab in patients with advanced melanoma

Start Date14 Mar 2023

Sponsor / Collaborator

Shanghai Celgen Bio-pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Shanghai Kangdai Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Kangdai Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Kangdai Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Kangdai Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

IND Approval

Phase 1 Clinical

1

Login to view more data